|
AU742521B2
(en)
*
|
1997-01-24 |
2002-01-03 |
Avi Biopharma, Inc. |
Method and conjugate for treating H. pylori infection
|
|
US6455495B1
(en)
*
|
1997-02-14 |
2002-09-24 |
The Salk Institute For Biological Studies |
Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
|
|
IL132941A0
(en)
|
1997-05-21 |
2001-03-19 |
Univ Leland Stanford Junior |
Composition and method for enhancing transport across biological membranes
|
|
US6958148B1
(en)
|
1998-01-20 |
2005-10-25 |
Pericor Science, Inc. |
Linkage of agents to body tissue using microparticles and transglutaminase
|
|
US6919076B1
(en)
|
1998-01-20 |
2005-07-19 |
Pericor Science, Inc. |
Conjugates of agents and transglutaminase substrate linking molecules
|
|
US20020064520A1
(en)
*
|
1999-08-19 |
2002-05-30 |
Yanina Rozenberg |
Targeted artificial gene delivery
|
|
US6669951B2
(en)
|
1999-08-24 |
2003-12-30 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into epithelial tissues
|
|
US6730293B1
(en)
|
1999-08-24 |
2004-05-04 |
Cellgate, Inc. |
Compositions and methods for treating inflammatory diseases of the skin
|
|
US7229961B2
(en)
|
1999-08-24 |
2007-06-12 |
Cellgate, Inc. |
Compositions and methods for enhancing drug delivery across and into ocular tissues
|
|
EP1210121A2
(en)
|
1999-08-24 |
2002-06-05 |
Cellgate Inc. |
Enhancing drug delivery across and into epithelial tissues using oligo arginine moieties
|
|
US6841542B2
(en)
|
2000-07-06 |
2005-01-11 |
Avi Biopharma, Inc. |
Transforming growth factor beta (TGF-β) blocking agent-treated stem cell composition and method
|
|
EP1301213B1
(en)
|
2000-07-21 |
2017-01-18 |
ReVance Therapeutics, Inc. |
Multi-component biological transport systems
|
|
JP2004523480A
(ja)
*
|
2000-08-22 |
2004-08-05 |
ニュー リバー ファーマシューティカルズ， インコーポレイテッド |
活性作用物質送達系ならびに活性作用物質の保護および投与方法
|
|
CA2428971A1
(en)
*
|
2000-11-14 |
2003-05-01 |
New River Pharmaceuticals Inc. |
Conjugates of a therapeutic agent and a peptide carrier
|
|
CA2477088A1
(en)
*
|
2002-02-22 |
2003-10-02 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
|
WO2004060403A2
(en)
|
2003-01-06 |
2004-07-22 |
Angiochem Inc. |
Aprotinin and anglos as carriers across the blood-brain barrier
|
|
US20050234002A1
(en)
|
2004-01-23 |
2005-10-20 |
Mourich Dan V |
Antisense oligomers and methods for inducing immune tolerance and immunosuppression
|
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
SG150570A1
(en)
|
2004-03-03 |
2009-03-30 |
Revance Therapeutics Inc |
Compositions and methods for topical diagnostic and therapeutic transport
|
|
DK1766012T3
(da)
|
2004-07-02 |
2011-09-19 |
Avi Biopharma Inc |
Antisense-antibakteriel fremgangsmåde og forbindelse
|
|
CA2596506C
(en)
|
2005-02-09 |
2021-04-06 |
Avi Biopharma, Inc. |
Antisense composition and method for treating muscle atrophy
|
|
EP1859041B2
(en)
|
2005-02-18 |
2014-11-19 |
Angiochem Inc. |
Aprotinin polypeptides for transporting a compound across the blood-brain barrier
|
|
SG160357A1
(en)
|
2005-03-03 |
2010-04-29 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
|
NZ560799A
(en)
|
2005-03-03 |
2009-10-30 |
Revance Therapeutics Inc |
Compositions and methods for topical application and transdermal delivery of an oligopeptide
|
|
US8067571B2
(en)
|
2005-07-13 |
2011-11-29 |
Avi Biopharma, Inc. |
Antibacterial antisense oligonucleotide and method
|
|
AU2006267051B2
(en)
|
2005-07-13 |
2013-03-07 |
Sarepta Therapeutics, Inc. |
Antisense antibacterial method and compound
|
|
ES2744225T3
(es)
|
2005-07-15 |
2020-02-24 |
Angiochem Inc |
Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos
|
|
US8501704B2
(en)
|
2005-11-08 |
2013-08-06 |
Sarepta Therapeutics, Inc. |
Immunosuppression compound and treatment method
|
|
EP1935434A1
(en)
*
|
2006-12-19 |
2008-06-25 |
Novosom AG |
Construction and use of transfection enhancer elements
|
|
US9365634B2
(en)
|
2007-05-29 |
2016-06-14 |
Angiochem Inc. |
Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
|
|
EP2271748B1
(en)
|
2008-03-20 |
2018-01-17 |
University of Florida Research Foundation, Inc. |
Enhancing vessel lesion homing and repair potential of stem cells
|
|
EP2143726A1
(en)
*
|
2008-07-11 |
2010-01-13 |
Novosom AG |
Nucleic acid comprising zwitterionic nucleotides
|
|
AU2009304560A1
(en)
|
2008-10-15 |
2010-04-22 |
Angiochem Inc. |
Conjugates of GLP-1 agonists and uses thereof
|
|
US9914754B2
(en)
|
2008-12-05 |
2018-03-13 |
Angiochem Inc. |
Conjugates of neurotensin or neurotensin analogs and uses thereof
|
|
AU2009335740B2
(en)
*
|
2008-12-17 |
2016-04-21 |
Sarepta Therapeutics, Inc. |
Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
|
|
AU2010239069B2
(en)
|
2009-04-20 |
2015-05-14 |
Angiochem Inc |
Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog
|
|
MX2011012875A
(es)
|
2009-06-05 |
2012-02-28 |
13Therapeutics Inc |
Peptidos inmunoreguladores y metodos de uso.
|
|
JP5932642B2
(ja)
|
2009-07-02 |
2016-06-08 |
アンジオケム インコーポレーテッド |
多量体ペプチドコンジュゲートおよびその使用
|
|
TWI620756B
(zh)
|
2010-05-28 |
2018-04-11 |
薩羅塔治療公司 |
具有經修飾之單元間連結及／或末端基團之寡核苷酸類似物
|
|
US10017763B2
(en)
|
2010-09-03 |
2018-07-10 |
Sarepta Therapeutics, Inc. |
dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups
|
|
WO2012138879A2
(en)
|
2011-04-06 |
2012-10-11 |
13Therapeutics, Inc. |
Peptides for the treatment of hearing
|
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
|
EA202090338A1
(ru)
|
2011-11-18 |
2021-04-30 |
Сарепта Терапьютикс, Инк. |
Функционально-модифицированные олигонуклеотиды и их субъединицы
|
|
ES2706198T3
(es)
|
2012-03-20 |
2019-03-27 |
Sarepta Therapeutics Inc |
Conjugados de ácido borónico de análogos de oligonucleótidos
|
|
GB201210358D0
(en)
*
|
2012-06-12 |
2012-07-25 |
Polytherics Ltd |
Complexes
|
|
WO2014026283A1
(en)
|
2012-08-14 |
2014-02-20 |
Angiochem Inc. |
Peptide-dendrimer conjugates and uses thereof
|
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
|
WO2016196897A1
(en)
|
2015-06-04 |
2016-12-08 |
Sarepta Therapeutics, Inc. |
Methods and compounds for treatment of lymphocyte-related diseases and conditions
|
|
EP3307326B9
(en)
|
2015-06-15 |
2021-02-24 |
Angiochem Inc. |
Methods for the treatment of leptomeningeal carcinomatosis
|
|
US20170100407A1
(en)
*
|
2015-10-07 |
2017-04-13 |
Cormedix Inc. |
Skin-penetrating formulation of taurolidine
|